Amanda F Saltzman1, Derek E Smith2, Dexiang Gao2, Debashis Ghosh3, Arya Amini4, Jennifer H Aldrink5, Roshni Dasgupta6, Kenneth W Gow7, Richard D Glick8, Peter F Ehrlich9, Nicholas G Cost10. 1. Department of Surgery, Division of Urology, University of Colorado School of Medicine, Aurora, CO. 2. Department of Pediatrics, University of Colorado School of Medicine & University of Colorado Cancer Center, Aurora, CO. 3. Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, CO. 4. Department of Radiation Oncology, University of Colorado School of Medicine and the Children's Hospital of Colorado, Aurora, CO. 5. Division of Pediatric Surgery, Department of Surgery, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, OH. 6. Division of Pediatric Surgery, Cincinnati Children's Hospital, Cincinnati, OH. 7. Division of Pediatric Surgery, Seattle Children's Hospital, Seattle, WA. 8. Division of Pediatric Surgery, Steven and Alexandra Cohen Medical Center of New York, New York, NY. 9. Department of Surgery, C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, MI. 10. Department of Surgery, Division of Urology, University of Colorado School of Medicine, Aurora, CO. Electronic address: nicholas.cost@childrenscolorado.org.
Abstract
PURPOSE: Current investigational priorities in the treatment of favorable histology Wilms tumor (FHWT) center on accurate staging and risk-stratification. The extent of lymph node (LN) sampling has not been clearly defined; its importance cannot be overstated as it guides adjuvant therapy. The identification of a minimum LN yield to minimize the risk of harboring occult metastatic disease could help development of surgical guidelines. This study focuses on using the beta-binomial distribution to estimate the risk of occult metastatic disease in patients with FHWT. MATERIALS & METHODS: The National Cancer Database was queried for patients with unilateral FHWT from 2004 to 2013. Data were used to characterize nodal positivity for patients who underwent surgery and had ≥1 positive LN and ≥2 LNs examined. The probability of missing a positive LN (i.e., false negative) for a given LN yield was calculated using an empirical estimation and the beta-binomial model. Patients were then stratified by tumor size. RESULTS: 422 patients met study criteria. To limit the chance of missing a positive LN to ≤10%, the empirical estimation and beta-binomial model estimated that 6 and 10 LNs needed to be sampled, respectively. Tumor size did not influence the result. Internal validation showed little variation to maintain a false negative rate ≤ 10%. CONCLUSIONS: Using mathematical modeling, it appears that the desired LN yield in FHWT to reduce the risk of false-negative LN sampling to ≤10% is between 6 and 10. The current analysis represents an objective attempt to determine the desired surgical approach to LN sampling to accurately stage patients with FHWT. LEVEL OF EVIDENCE: II.
PURPOSE: Current investigational priorities in the treatment of favorable histology Wilms tumor (FHWT) center on accurate staging and risk-stratification. The extent of lymph node (LN) sampling has not been clearly defined; its importance cannot be overstated as it guides adjuvant therapy. The identification of a minimum LN yield to minimize the risk of harboring occult metastatic disease could help development of surgical guidelines. This study focuses on using the beta-binomial distribution to estimate the risk of occult metastatic disease in patients with FHWT. MATERIALS & METHODS: The National Cancer Database was queried for patients with unilateral FHWT from 2004 to 2013. Data were used to characterize nodal positivity for patients who underwent surgery and had ≥1 positive LN and ≥2 LNs examined. The probability of missing a positive LN (i.e., false negative) for a given LN yield was calculated using an empirical estimation and the beta-binomial model. Patients were then stratified by tumor size. RESULTS: 422 patients met study criteria. To limit the chance of missing a positive LN to ≤10%, the empirical estimation and beta-binomial model estimated that 6 and 10 LNs needed to be sampled, respectively. Tumor size did not influence the result. Internal validation showed little variation to maintain a false negative rate ≤ 10%. CONCLUSIONS: Using mathematical modeling, it appears that the desired LN yield in FHWT to reduce the risk of false-negative LN sampling to ≤10% is between 6 and 10. The current analysis represents an objective attempt to determine the desired surgical approach to LN sampling to accurately stage patients with FHWT. LEVEL OF EVIDENCE: II.
Authors: Joshua N Honeyman; Barrie S Rich; Maureen P McEvoy; Molly A Knowles; Glenn Heller; Edward Riachy; Rachel Kobos; Neerav Shukla; Suzanne L Wolden; Peter G Steinherz; Michael P La Quaglia Journal: J Pediatr Surg Date: 2012-06 Impact factor: 2.545
Authors: Peter F Ehrlich; Michael L Ritchey; Tomas E Hamilton; Gerald M Haase; San Ou; Norman Breslow; Paul Grundy; Daniel Green; Patricia Norkool; Jennifer Becker; Robert C Shamberger Journal: J Pediatr Surg Date: 2005-01 Impact factor: 2.545
Authors: Kristian Storli; Christian Fredrik Lindboe; Camilla Kristoffersen; Karina Kleiven; Karl Søndenaa Journal: APMIS Date: 2010-12-01 Impact factor: 3.205
Authors: Kathleen Kieran; James R Anderson; Jeffrey S Dome; Peter F Ehrlich; Michael L Ritchey; Robert C Shamberger; Elizabeth J Perlman; Daniel M Green; Andrew M Davidoff Journal: J Pediatr Surg Date: 2012-04 Impact factor: 2.545
Authors: Wassim Kassouf; Robert S Svatek; Shahrokh F Shariat; Giacomo Novara; Seth P Lerner; Yves Fradet; Patrick J Bastian; Armen Aprikian; Pierre I Karakiewicz; Hans Martin Fritsche; Colin P N Dinney; Derya Tilki; Ashish M Kamat; Jonathan I Izawa; Vincenzo Ficarra; Yair Lotan; Arthur I Sagalowsky; Mark P Schoenberg; Eila C Skinner Journal: Urol Oncol Date: 2011-04-08 Impact factor: 3.498
Authors: Ziv Gil; Diane L Carlson; Jay O Boyle; Dennis H Kraus; Jatin P Shah; Ashok R Shaha; Bhuvanesh Singh; Richard J Wong; Snehal G Patel Journal: Cancer Date: 2009-12-15 Impact factor: 6.860
Authors: Jonathan P Walker; Jared S Johnson; Megan M Eguchi; Amanda F Saltzman; Myles Cockburn; Nicholas G Cost Journal: J Pediatr Urol Date: 2019-11-06 Impact factor: 1.830